Impaired Fasting Glucose and Impaired Glucose Tolerance
David M. Nathan(Harvard University), Bernard Zinman(Mount Sinai Hospital)
Cited by 1,391
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
|Diabetes Care|2007|1.5k